Protocol · Oncology Support
Endometrial Cancer Supportive Care Protocol
Vitamin D and Omega-3 Fatty Acids are the core of this stack, with 5 supporting supplements. Each row gives the amount the protocol lists and the grade our evidence database holds for that supplement in Endometrial Cancer Supportive Care.
We are re-verifying the studies cited on protocol pages; only confirmed citations are shown.
The stack
7 supplements · none graded yet
| Grade | Supplement | Amount listed | Why it’s in the stack | Evidence on file |
|---|---|---|---|---|
| Primary stackThe core of this protocol | ||||
| Vitamin D | Amount listed: 2,000–4,000 IU daily (maintain adequate levels) | Supports immune function; deficiency associated with worse outcomes; may affect cell differentiation | Not graded yet | |
| Omega-3 Fatty Acids | Amount listed: 2–3 g EPA+DHA daily | Anti-inflammatory; may help preserve muscle mass during treatment | Not graded yet | |
| Supporting stackListed as additions to the core | ||||
| Protein Supplements | Amount listed: 1.2–1.5 g protein/kg body weight daily | Supports nutrition and muscle maintenance during cancer treatment | Not graded yet | |
| Curcumin | Amount listed: 500–2,000 mg daily with enhanced absorption | Anti-inflammatory; laboratory studies show effects on endometrial cancer cells; may help with treatment side effects | Not graded yet | |
| Green Tea Extract | Amount listed: 300–500 mg EGCG daily | EGCG has anti-cancer properties in laboratory studies; antioxidant effects | Not graded yet | |
| Probiotics | Amount listed: 10–20 billion CFU daily | Supports gut health during treatment; may help with treatment-related GI symptoms | Not graded yet | |
| Ginger | Amount listed: 250–1,000 mg daily around treatment | Helps with chemotherapy-induced nausea; anti-inflammatory | Not graded yet | |
How this protocol works
In plain language
Endometrial cancer is cancer that begins in the lining of the uterus (endometrium). It is the most common gynecological cancer in developed countries, with most cases occurring after menopause.
TYPES:
- Type I (80-90%): Estrogen-dependent, typically endometrioid adenocarcinoma, usually better prognosis
- Type II (10-20%): Non-estrogen-dependent, includes serous and clear cell, more aggressive
RISK FACTORS:
- Obesity (major risk factor)
- Diabetes
- PCOS (polycystic ovary syndrome)
- Estrogen therapy without progesterone
- Tamoxifen use
- Nulliparity (never having given birth)
- Early menarche/late menopause
- Lynch syndrome (hereditary)
SYMPTOMS:
- Abnormal uterine bleeding (especially postmenopausal)
- Pelvic pain
- Pain during intercourse
- Unexplained weight loss (advanced)
CRITICAL: Endometrial cancer requires specialized gynecologic oncology care. This protocol is SUPPORTIVE ONLY.
TREATMENT:
- Surgery: Total hysterectomy with bilateral salpingo-oophorectomy (standard)
- Radiation: Vaginal brachytherapy and/or external beam
- Chemotherapy: For advanced or high-risk disease
- Hormone therapy: For select cases
- Immunotherapy: For MSI-high/dMMR tumors
NUTRITIONAL GOALS:
- Maintain healthy weight (obesity worsens outcomes)
- Support immune function
- Manage treatment side effects
- Adequate protein for healing
Vitamin D* supports immune function and is often deficient.
Protein* helps maintain muscle mass during treatment.
Ginger* may help with chemotherapy-induced nausea.
Expected timeline: Treatment is typically surgical with adjuvant therapy as needed. Supportive care continues through treatment and recovery.